Browse the evidence

Obesity and metabolic disease are driven by a misalignment between behaviors (feeding/fasting rhythms, physical activity) and tissue functions (organ clocks), regulated by circadian molecular clocks in the brain and periphery.

Your body's organs operate on a 24-hour schedule. Try to align your eating and sleeping times with your natural circadian rhythm. Eating large meals late at night or irregularly can disrupt the internal clocks in your liver, muscle, and fat, leading to metabolic issues. Consistent meal times and adequate sleep support better metabolic health.

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, produces significant weight loss and reduced hunger in patients with severe obesity linked to specific genetic deficiencies (POMC, PCSK1, LEPR, BBS, Alström, SRC1, SH2B1).

For individuals with severe obesity caused by specific genetic mutations (like POMC or LEPR deficiencies), Setmelanotide is a highly effective treatment that significantly reduces body weight and hunger. It requires regular injections, and patients should be prepared for common side effects like skin darkening and injection site reactions, which are generally manageable. This treatment is specifically indicated for genetic forms of obesity, not general weight loss.

Obesity exacerbates cardiovascular disease (CVD) risk and mortality through structural and metabolic mechanisms, including visceral fat deposition, pro-inflammatory cytokine release (TNF-α, IL-1, IL-6), and lipotoxicity from free fatty acids and ceramides.

Obesity is not just about weight; it is a state of chronic inflammation and metabolic signaling disruption that directly harms the heart and blood vessels. Managing obesity requires addressing these underlying biological mechanisms, such as reducing visceral fat and inflammation, to lower cardiovascular risk.

Activation of the AMPK pathway in adipocytes inhibits adipogenesis, enhances insulin sensitivity, promotes thermogenesis, and leads to weight loss, whereas activation in the central nervous system results in weight gain and increased appetite.

While activating AMPK in fat cells can help burn fat and improve insulin sensitivity, activating it in the brain can have the opposite effect, increasing appetite and weight gain. This highlights the complexity of targeting metabolic pathways.

Discontinuation of GLP-1 RA or GIP/GLP-1 RA therapy (liraglutide, semaglutide, tirzepatide) leads to rapid and substantial weight regain, effectively reversing the majority of metabolic benefits achieved during treatment.

If you stop taking GLP-1 or GIP/GLP-1 medications (like semaglutide or tirzepatide), you will likely regain most of the weight you lost. The drugs work by altering hormonal signals that regulate hunger and metabolism; when you stop, those signals revert. To maintain weight loss, you likely need to continue the medication long-term or adopt a rigorous, sustainable lifestyle intervention that mimics the drug's effects, though current evidence suggests pharmacological support is often necessary to prevent rebound.

Skeletal muscle mass loss with advancing age is primarily driven by anabolic resistance (blunted muscle protein synthesis response to protein and exercise) rather than increased protein breakdown, with losses accelerating after the 7th decade of life.

Focus on maintaining muscle mass through regular resistance exercise and adequate protein intake, especially as you enter your 60s and beyond. The rate of loss accelerates significantly after age 70, making early and consistent intervention critical to preserving independence and healthspan.

Muscle function (strength and power) declines at a substantially faster rate than muscle mass, with power loss beginning as early as young adulthood (20-39 years).

Prioritize power training (moving weight quickly) in addition to strength training. Since power loss starts in your 20s and 30s, maintaining explosive movement capability is key to preventing future frailty and falls.

Physical inactivity and hospitalization-induced bed rest accelerate muscle mass and function loss in older adults at a rate 3-6 times faster than in younger adults, with incomplete recovery.

If you are older, avoid unnecessary bed rest. If hospitalization is unavoidable, ask for early mobilization and physical therapy to mitigate the rapid 3-6x accelerated muscle loss that occurs during inactivity.

Tirzepatide treatment in people with type 2 diabetes shifts body fat distribution toward a more balanced pattern by significantly reducing visceral adipose tissue (VAT) and liver fat (LF) while preserving abdominal subcutaneous adipose tissue (aSAT) relative to the amount of weight lost.

If you have type 2 diabetes and are prescribed tirzepatide, expect significant reductions in dangerous visceral and liver fat. Importantly, the drug appears to preserve your subcutaneous fat (the fat under the skin) better than other weight-loss methods might, leading to a healthier overall fat distribution pattern. This shift occurs alongside weight loss and improves cardiometabolic risk markers.

Time-restricted eating (8-hour window) combined with resistance training improves upper-body high-speed strength (peak force and dynamic strength index) compared to habitual diet, while potentially impairing lower-body explosive performance.

If you are training for upper-body explosive power (like throwing or punching), an 8-hour eating window combined with heavy resistance training may boost your performance more than eating normally. However, if your goal is lower-body explosiveness (like jumping or sprinting), sticking to your normal eating schedule might yield better results. Body composition changes (fat loss) were similar in both groups.

Humans exhibit sensitivity to meal energy density (ED) by adjusting meal size to minimize acute aversive effects of overconsumption, specifically through a nonlinear relationship where calorie-content signals dominate at high EDs (>1.41-1.75 kcal/g).

Your body naturally regulates intake based on how energy-dense your food is. When you eat foods with high energy density (above ~1.5 kcal/g), your body uses calorie-sensing signals to reduce your meal size, preventing overconsumption. This is a learned and biological response, not just stomach volume. Focus on understanding that high-energy foods trigger different satiety signals than low-energy, high-volume foods.

Adherence to a healthy low-carbohydrate diet (low low-quality carbs, high unsaturated fat, high plant protein) is associated with marginally lower total mortality (HR 0.95) in middle-aged and older adults, whereas overall or unhealthy LCDs (high saturated fat/animal protein) increase mortality risk.

If you follow a low-carbohydrate diet, prioritize unsaturated fats (like olive oil, nuts) and plant proteins (legumes, grains) while minimizing saturated fats and refined carbohydrates. Simply reducing carbs without improving food quality may increase your risk of death.

Adherence to a healthy low-fat diet (low saturated fat, high high-quality carbohydrates, high plant protein) is associated with significantly lower total (HR 0.82), cardiovascular (HR 0.84), and cancer (HR 0.82) mortality in middle-aged and older adults.

Adopt a low-fat diet that emphasizes high-quality carbohydrates (whole grains, fruits, vegetables) and plant proteins (legumes, nuts) while strictly limiting saturated fats. This pattern is associated with an 18% lower risk of death from all causes, heart disease, and cancer in older adults.

Isocaloric replacement of 3% energy from low-quality carbohydrates or saturated fat with plant protein is associated with significantly lower total, cardiovascular, and cancer mortality.

Replace 3% of your daily energy intake from refined carbohydrates and saturated fats with plant protein sources like beans, lentils, nuts, and whole grains. This simple substitution is associated with a 10% lower risk of death from all causes.

Delayed gastric emptying contributes to weight loss with GLP-1 agonists, but central appetite suppression is the predominant mechanism.

While GLP-1 drugs slow stomach emptying, this only explains about 20% of the weight loss. The main driver is reduced hunger and food intake due to brain signaling.

Semaglutide (2.4 mg/week) provides significantly better economic value for weight reduction than liraglutide (3 mg/day), with a lower cost needed to treat per 1% body weight reduction.

If you are choosing between semaglutide and liraglutide for weight loss in the US, semaglutide is the more economically efficient option. It achieves nearly double the weight loss (12.4% vs 5.4%) for a lower cost per percentage point of weight lost, despite having a higher total therapy cost. The weekly injection schedule may also improve convenience and adherence compared to daily injections.

Baseline Respiratory Quotient (RQ) can predict which diet (Low-Carb or Low-Fat) will be more effective for an individual's short-term weight loss.

If you can measure your baseline Respiratory Quotient (RQ), a high RQ suggests you might lose more weight on a Low-Carb diet, while a low RQ might suggest a Low-Fat diet could be more effective.

GLP-1-based therapies (liraglutide, semaglutide, tirzepatide) reduce blood pressure in individuals with overweight or obesity, with tirzepatide demonstrating the greatest magnitude of reduction.

If you have high blood pressure and carry extra weight, GLP-1 medications like semaglutide or tirzepatide can lower your blood pressure, sometimes allowing you to take fewer other blood pressure pills. Tirzepatide appears to lower blood pressure more than other options in this class. These are weekly injections, which might be easier to manage than daily pills, though they can cause stomach side effects.

Licensed weight-lowering pharmacotherapies (GLP-1RAs, naltrexone/bupropion, phentermine/topiramate) improve self-reported physical function, but do not significantly improve objectively measured physical function, cardiorespiratory fitness, or physical activity levels.

If you are using FDA/EMA-approved weight loss medications, expect improvements in how you feel you function in daily life (self-reported physical function). However, do not expect these medications alone to significantly boost your actual exercise capacity, VO2 max, or daily activity levels without dedicated exercise training. The benefits are modest and primarily subjective.

In individuals with overweight or obesity at high risk of type 2 diabetes, a trajectory of weight loss followed by weight regain results in a net loss of fat-free mass (FFM) despite fat mass (FM) returning to baseline levels.

If you are overweight or obese and have experienced a cycle of losing weight and then gaining it back, be aware that your body composition may have worsened even if your weight is back to where it started. Specifically, you may have lost muscle mass (fat-free mass) while regaining fat. To counteract this, prioritize resistance training and adequate protein intake during any future weight loss attempts to preserve muscle, as simply returning to your starting weight does not restore your previous body composition.

A trajectory of weight gain followed by weight loss results in a net gain in fat mass (FM) despite fat-free mass (FFM) returning to baseline levels.

If you have gained weight and then lost it back to your starting weight, your body composition may not be the same as it was before. You may have more fat and less muscle than you did initially. To ensure you are maintaining a healthy body composition, incorporate strength training and monitor body composition metrics, not just total body weight.

Transitioning from a very-low-carbohydrate diet to a high-carbohydrate diet requires several weeks (approximately 5-9 weeks) for full glycemic adaptation, meaning a 3-day preparation period is insufficient for accurate diabetes screening in habitual low-carb dieters.

If you have been eating a very low-carb diet and plan to switch to a higher-carb diet (or undergo a diabetes test), do not expect your blood sugar to stabilize immediately. It can take 5 to 9 weeks for your body to fully adapt to processing carbohydrates again. If you are getting a diabetes screening, inform your doctor about your recent low-carb diet history, as a standard 3-day prep may yield a false positive.

Dual GIP and GLP-1 receptor agonist tirzepatide significantly improves kidney outcomes in adults with type 2 diabetes and increased cardiovascular risk compared to insulin.

If you have Type 2 Diabetes and are at risk for kidney disease, ask your doctor about tirzepatide. It is a once-weekly injection that has been shown to significantly reduce the risk of serious kidney problems compared to insulin, while also helping with blood sugar and weight control. You do not need to adjust the dose even if you have kidney disease.

GLP-1 receptor agonists (specifically tirzepatide and liraglutide) significantly reduce Obstructive Sleep Apnea (OSA) severity, measured by Apnea-Hypopnea Index (AHI), primarily through substantial weight loss, while also providing independent cardiovascular benefits such as reduced vascular inflammation and improved endothelial function.

If you have OSA and obesity, GLP-1 agonists like tirzepatide or liraglutide can significantly reduce your sleep apnea severity (AHI) and improve cardiovascular health, largely by helping you lose weight. While CPAP is still the gold standard for mechanically opening the airway, GLP-1s offer a pharmacological option that also targets inflammation and blood pressure. Expect weekly injections and potential gastrointestinal side effects, which may affect adherence. Discuss with your doctor if you are a candidate, especially if you have Type 2 Diabetes.